Fig. 1From: The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studiesCorrelation between MBDA score and DAS28. a MBDA score versus DAS28-ESR at baseline (n = 46). b MBDA score versus DAS28-ESR at 6 months (n = 42). c ∆MBDA score versus ∆DAS28-ESR, from baseline to 6 months (n = 38). d MBDA score versus DAS28-hsCRP at baseline (n = 25). e MBDA score versus DAS28-hsCRP at 6 months (n = 24). f ∆MBDA score versus ∆DAS28-hsCRP, from baseline to 6 months (n = 23). Negative change values represent improvement over 6 monthsBack to article page